 | Up a level |
Stathis, Anastasios; Pirosa, Maria Cristina; Orsucci, Lorella; Feugier, Pierre; Tani, Monica; Ghesquières, Hervé; Musuraca, Gerardo; Rossi, Francesca Gaia; Merli, Francesco; Guièze, Romain; Gyan, Emmanuel; Gini, Guido; Marino, Dario; Gressin, Remy; Morschhauser, Franck; Cavallo, Federica; Palombi, Francesca; Conconi, Annarita; Tessoulin, Benoît; Tilly, Hervé; ... (2024). IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica - the hematology journal, 109(8), pp. 2564-2573. Ferrata-Storti Foundation 10.3324/haematol.2023.283918
Kamdar, Manali; Solomon, Scott R; Arnason, Jon; Johnston, Patrick B; Glass, Bertram; Bachanova, Veronika; Ibrahimi, Sami; Mielke, Stephan; Mutsaers, Pim; Hernandez-Ilizaliturri, Francisco; Izutsu, Koji; Morschhauser, Franck; Lunning, Matthew; Maloney, David G; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Stepan, Lara; Ogasawara, Ken; Mack, Timothy; ... (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), pp. 2294-2308. Elsevier 10.1016/S0140-6736(22)00662-6
